Concepedia
4
Publications
91
Citations
H-Index
2023
Active since
Affiliations
AstraZeneca (United Kingdom)(Current)
AstraZeneca (Sweden)
Medicines Evaluation Unit
AstraZeneca (Spain)
AstraZeneca (Poland)
Fred Reid is an author at AstraZeneca (United Kingdom).
Publications per year
2023–2025
A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease
Fred Reid, Dave Singh, Muna Albayaty et al. · Clinical Pharmacology & Therapeutics · 2023 · 37 citations · Full text
A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4
Dave Singh, Patricia Guller, Fred Reid et al. · European Respiratory Journal · 2025 · 32 citations
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
Muhammad Waqas Sadiq, Hongtao Yu, Magnus Åstrand et al. · British Journal of Clinical Pharmacology · 2024 · 12 citations · Full text
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles W. Carroll et al. · ERJ Open Research · 2023 · 10 citations · Full text
Rows per page
1–4 of 4